| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain;
Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; and
Unit of Molecular Genetics, Marqués de Valdecilla University Hospital, Santander, Spain
1Correspondence: Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, 28040 Madrid, Spain. E-mail: mgp{at}bbm1.ucm.es
ABSTRACT
Melanoma causes the greatest number of skin cancer-related deaths worldwide. Despite intensive research, prevention and early detection are the only effective measures against melanoma, so new therapeutic strategies are necessary for the management of this devastating disease. Here, we evaluated the efficacy of cannabinoid receptor agonists, a new family of potential antitumoral compounds, at skin melanoma. Human melanomas and melanoma cell lines express CB1 and CB2 cannabinoid receptors. Activation of these receptors decreased growth, proliferation, angiogenesis and metastasis, and increased apoptosis, of melanomas in mice. Cannabinoid antimelanoma activity was independent of the immune status of the animal, could be achieved without overt psychoactive effects and was selective for melanoma cells vs. normal melanocytes. Cannabinoid antiproliferative action on melanoma cells was due, at least in part, to cell cycle arrest at the G1-S transition via inhibition of the prosurvival protein Akt and hypophosphorylation of the pRb retinoblastoma protein tumor suppressor. These findings may contribute to the design of new chemotherapeutic strategies for the management of melanoma.—Blázquez, C., Carracedo, A., Barrado, L., Real, P. J., Fernández-Luna, J. L., Velasco, G., Malumbres, M., and Guzmán, M. Cannabinoid receptors as novel targets for the treatment of melanoma.
This article has been cited by other articles:
|
|
 |
|
  N. Dobrosi, B. I. Toth, G. Nagy, A. Dozsa, T. Geczy, L. Nagy, C. C. Zouboulis, R. Paus, L. Kovacs, and T. Biro Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling FASEB J, October 1, 2008; 22(10): 3685 - 3695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zheng, A. M. Bode, Q. Zhao, Y.-Y. Cho, F. Zhu, W.-Y. Ma, and Z. Dong The Cannabinoid Receptors Are Required for Ultraviolet-Induced Inflammation and Skin Cancer Development Cancer Res., May 15, 2008; 68(10): 3992 - 3998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Blazquez, M. Salazar, A. Carracedo, M. Lorente, A. Egia, L. Gonzalez-Feria, A. Haro, G. Velasco, and M. Guzman Cannabinoids Inhibit Glioma Cell Invasion by Down-regulating Matrix Metalloproteinase-2 Expression Cancer Res., March 15, 2008; 68(6): 1945 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Paradisi, N. Pasquariello, D. Barcaroli, and M. Maccarrone Anandamide Regulates Keratinocyte Differentiation by Inducing DNA Methylation in a CB1 Receptor-dependent Manner J. Biol. Chem., March 7, 2008; 283(10): 6005 - 6012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sarfaraz, V. M. Adhami, D. N. Syed, F. Afaq, and H. Mukhtar Cannabinoids for Cancer Treatment: Progress and Promise Cancer Res., January 15, 2008; 68(2): 339 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Telek, T. Biro, E. Bodo, B. I. Toth, I. Borbiro, G. Kunos, and R. Paus Inhibition of human hair follicle growth by endo- and exocannabinoids FASEB J, November 1, 2007; 21(13): 3534 - 3541. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
